vimarsana.com

Latest Breaking News On - Plasma detect - Page 1 : vimarsana.com

Laboratory Corporation of America Holdings (NYSE:LH) Q1 2024 Earnings Call Transcript

Laboratory Corporation of America Holdings beats earnings expectations. Reported EPS is $3.68, expectations were $3.46.

United statesGlenn eisenbergChristin odonnellPatrick donnellyAnn hynesJack meehanAdam schechterMichael chernyErin wrightAmerica holdingsBiopharm laboratory servicesLabcorp holdings incCentral labLaboratory corpLaboratory corporation of america holdingsFortrea holdings inc

Labcorp Announces 2024 First Quarter Results

Updates Full-Year Guidance Results from Continuing Operations for first quarter 2024 versus last year:Revenue: $3.18 billion versus $3.04 billion or up 4.6% | Base Business grew 6.7%Diluted EPS:.

United statesAdam schechterEarly development research laboratoriesCommercialization servicesClinical developmentBioreference healthFortrea holdings incBeacon laboratory benefits solutionsLaboratory corporation of americaLaboratory corporation of america holdingsLabcorp holdings incBiopharma laboratory servicesBaystate healthDrug administrationUpdates full yearContinuing operations

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to advancing cancer research and patient care on a global scale. The announcement underscores Labcorp's dedication to .

San diegoUnited statesBrian caveneyKimbrel arculeoChristin odonnellDevelopment of antibody drug conjugatesAmerican association for cancer researchPlasma detectPlasma completeLabcorp plasma detectAmerican associationCancer researchGene therapyAntibody drug conjugatesChristino donnell

Labcorp Announces Expansion of Precision Oncology Portfolio to Support Pharmaceutical, Biopharma, and Clinical Research in Advancing Drug Development Programs

BURLINGTON - Labcorp , a global leader of innovative and comprehensive laboratory services, announced today the strategic expansion of its precision oncology portfolio, solidifying its commitment to.

United statesSan diegoKimbrel arculeoChristin odonnellBrian caveneyDevelopment of antibody drug conjugatesAmerican association for cancer researchLabcorp plasma detectLabcorp plasma completePlasma detectCancer researchPlasma completeGene therapyAntibody drugNews publishing

Labcorp Launches Labcorp® Plasma Detect™ Extending Leadership into Molecular Residual Disease (MRD) Clinical Research

Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today the launch of Labcorp® Plasma Detect™, the first clinically validated, tumor-informed, whole-genome sequencing circulating tumor DNA (ctDNA) molecular residual disease (MRD) solution in early stage colon cancer .

United statesChristin odonnellKimbrel arculeoRemond fijnemanShakti ramkissoonNetherlands cancer instituteAmerican association for cancer researchGenome diagnostics incLabcorp plasma detectPlasma detectPlasma focusPlasma completePersonal genome diagnosticsAmerican associationCancer researchChristino donnell

vimarsana © 2020. All Rights Reserved.